169 related articles for article (PubMed ID: 34656433)
1. Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
Hao Z; Sekkath Veedu J
Clin Lung Cancer; 2022 Jan; 23(1):14-20. PubMed ID: 34656433
[TBL] [Abstract][Full Text] [Related]
2. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
4. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
5. Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review.
Yuan G; Liu X; Zhang X; Song W; Lu J; Ding Z; Chen X
Front Immunol; 2023; 14():1267606. PubMed ID: 37781394
[TBL] [Abstract][Full Text] [Related]
6. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Song Z; Shao L; Lin B; Zhang Y
Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
[TBL] [Abstract][Full Text] [Related]
7. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
10. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
[TBL] [Abstract][Full Text] [Related]
11. Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y; Chen K; Fan Y
Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
[TBL] [Abstract][Full Text] [Related]
12. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
13. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Ortega-Franco A; Ackermann C; Paz-Ares L; Califano R
ESMO Open; 2021 Feb; 6(1):100003. PubMed ID: 33450659
[TBL] [Abstract][Full Text] [Related]
14. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Zhou K; Wen F; Zhang P; Zhou J; Zheng H; Sun L; Li Q
Clin Transl Oncol; 2018 Jun; 20(6):768-774. PubMed ID: 29098555
[TBL] [Abstract][Full Text] [Related]
16. Update 2021: Management of Small Cell Lung Cancer.
Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
[TBL] [Abstract][Full Text] [Related]
17. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Farago AF; Yeap BY; Stanzione M; Hung YP; Heist RS; Marcoux JP; Zhong J; Rangachari D; Barbie DA; Phat S; Myers DT; Morris R; Kem M; Dubash TD; Kennedy EA; Digumarthy SR; Sequist LV; Hata AN; Maheswaran S; Haber DA; Lawrence MS; Shaw AT; Mino-Kenudson M; Dyson NJ; Drapkin BJ
Cancer Discov; 2019 Oct; 9(10):1372-1387. PubMed ID: 31416802
[TBL] [Abstract][Full Text] [Related]
18. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC; Torri V; Michetti G; Lo Dico M; La Verde N; Aglione S; Mancuso A; Gallerani E; Galetta D; Martelli O; Collovà E; Fatigoni S; Ghidini A; Saggia C; Bareggi C; Rossi A; Farina G; Thatcher N; Blackhall F; Lorigan P; Califano R
Lung Cancer; 2011 Jun; 72(3):378-83. PubMed ID: 20950888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
